Additional bioanalytical, dose analysis and DSMB costs for PTI-125 development

点击翻译按钮获取中文摘要

PTI-125 is a novel small molecule AD therapeutic candidate with a novel target and mechanism of action. PTI-125 binds and reverses an altered conformation of the scaffolding protein filamin A (FLNA) to prevent Aβ42’s tight binding to and toxic signaling via the α7-nicotinic acetylcholine receptor (α7nAChR) as well as Aβ42’s aberrant activation of toll-like receptor 4 (TLR4). Hence, by restoring FLNA’s native shape and blocking these two toxic cascades, PTI-125 reduces both tau hyperphosphorylation and neuroinflammation. Downstream effects include reduced neurofibrillary lesions and amyloid deposits, suggesting disease modification, and improved synaptic plasticity and function of α7nAChR, NMDAR and insulin receptors, suggesting symptomatic improvement. We will pursue a label claim of symptomatic improvement instead of the more difficult claim of disease modification. An IND has been filed and the first-inhuman trial will start August 9, 2017. The current administrative supplement proposal includes additional development work related to this first-in-human clinical trial and the ongoing interim 3-month oral toxicity study in dog. These activities include 1) the Data and Safety Monitoring Board, 2) the bioanalytical method adaptation and validation for use in human plasma, 3) the bioanalysis of plasma samples from the 3-month dog study, 4) the dose analysis for the dosing solutions used in the 3-month dog study, required by GLP regulations, and 5) the cost of the recently completed independent audit of the previous SBIR grant that closed Dec. 31, 2016. All these activities are necessary for the continued development of this novel AD therapeutic candidate.